The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparison of the frequency of adverse events requiring interventions determined by telephone follow up in hepatocellular carcinoma patients treated with sorafenib and lenvatinib.
 
Koki Morishita
No Relationships to Disclose
 
Hidetaka Suzuki
No Relationships to Disclose
 
Junko Tauchi
No Relationships to Disclose
 
Misaki K Takeno
No Relationships to Disclose
 
Kohei Hayashi
No Relationships to Disclose
 
Masafumi Ikeda
Honoraria - Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Dainippon Sumitomo Pharma; Dainippon Sumitomo Pharma; Dainippon Sumitomo Pharma; Dainippon Sumitomo Pharma; EA Pharma; EA Pharma; EA Pharma; EA Pharma; Eisai; Eisai; Eisai; Eisai; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Kaken Pharmaceutical; Kaken Pharmaceutical; Kaken Pharmaceutical; Kaken Pharmaceutical; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; MSD; MSD; MSD; MSD; Mylan; Mylan; Mylan; Mylan; Novartis; Novartis; Novartis; Novartis; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma; Teijin Pharma; Teijin Pharma; Teijin Pharma
Consulting or Advisory Role - ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Eisai; Eisai; Eisai; Eisai; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Micron; Micron; Micron; Micron; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Shire; Shire; Shire; Shire; Teijin Pharma; Teijin Pharma; Teijin Pharma; Teijin Pharma
Research Funding - ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Bayer Yakuhin (Inst); Bayer Yakuhin (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); J-Pharma (Inst); J-Pharma (Inst); J-Pharma (Inst); J-Pharma (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); NanoCarrier (Inst); NanoCarrier (Inst); NanoCarrier (Inst); NanoCarrier (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)